Skip to main content
4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.46
+0.01 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
9.42
-0.04 (-0.42%)
After-hours: Apr 28, 2026, 4:10 PM EDT

4D Molecular Therapeutics Revenue

In the year 2025, 4D Molecular Therapeutics had annual revenue of $85.21M with 230,194.59% growth. 4D Molecular Therapeutics had revenue of $85.09M in the quarter ending December 31, 2025, with 8,508,900.00% growth.

Revenue (ttm)
$85.21M
Revenue Growth
+230,194.59%
P/S Ratio
5.67
Revenue / Employee
$434,740
Employees
196
Market Cap
482.95M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202585.21M85.17M230,194.59%
Dec 31, 202437.00K-20.69M-99.82%
Dec 31, 202320.72M17.59M562.29%
Dec 31, 20223.13M-14.91M-82.65%
Dec 31, 202118.04M4.43M32.52%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Valneva SE 205.07M
Ginkgo Bioworks Holdings 170.16M
ADC Therapeutics 81.36M
Entrada Therapeutics 25.42M
Prelude Therapeutics 12.14M
Armata Pharmaceuticals 4.90M
Upstream Bio 2.85M
Revenue Rankings

FDMT News

More News